Abdelfateh Chourir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdelfateh Chourir has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Naima El Hafidi
Pediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
2 shared publications Aya Abidou
Pediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
1 shared publication- Aya Abidou
Pediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
1 shared publication - Azeddine Ibrahimi
Medical Biotechnology Laboratory, Faculty of Medicine and Pharmacy, Mohamed 5 Rabat University, Rabat 10000, Morocco
1 shared publication Boutaina Elgharbaoui
Pediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
1 shared publicationFarah Makhloufi
Pediatric Translational Clinical Research Unit, Medical Biotechnology lab (MedBiotech) Bioinova Research Center, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco
1 shared publication
Latest Publications
- 9 September 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 11005-11020
Computational discovery of novel human rhinovirus 3 C protease inhibitors: molecular docking, dynamic simulations, free energy landscape, MMPBSA and ADMET analysis
- 9 September 2026
- Published by Springer Nature in Molecular Diversity
- Vol. 30 (6) , 11005-11020
Computational discovery of novel human rhinovirus 3 C protease inhibitors: molecular docking, dynamic simulations, free energy landscape, MMPBSA and ADMET analysis
- Open Access
- 13 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Design of a multiepitope immunotherapy for fish allergy
Fish allergy is a significant global health concern and often leads to persistent and potentially severe hypersensitivity reactions. The molecular heterogeneity of fish allergens poses challenges for developing broadly applicable immunotherapies. In this study, an integrated immunoinformatics pipeline was used to design a multi-epitope vaccine construct targeting three major fish allergens: parvalbumin, enolase, and aldolase. Predicted B-cell and T-cell epitopes were screened for immunogenicity, non-allergenicity, and lack of toxicity, and the selected peptides were assembled into a 432-amino acid chimeric construct using rationally chosen linkers to facilitate antigen processing. Computational analyses predicted the construct to exhibit favorable physicochemical properties, including stability, solubility, and a broad theoretical population coverage. Docking and molecular dynamics simulations suggested a potential interaction with Toll-like receptor 4, offering preliminary insight into possible innate immune engagement. As these findings are entirely in silico, they represent a theoretical framework; experimental validation is necessary to determine the construct’s biological behavior, safety, and immunological relevance.
- 13 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessDesign of a multiepitope immunotherapy for fish allergy
Fish allergy is a significant global health concern and often leads to persistent and potentially severe hypersensitivity reactions. The molecular heterogeneity of fish allergens poses challenges for developing broadly applicable immunotherapies. In this study, an integrated immunoinformatics pipeline was used to design a multi-epitope vaccine construct targeting three major fish allergens: parvalbumin, enolase, and aldolase. Predicted B-cell and T-cell epitopes were screened for immunogenicity, non-allergenicity, and lack of toxicity, and the selected peptides were assembled into a 432-amino acid chimeric construct using rationally chosen linkers to facilitate antigen processing. Computational analyses predicted the construct to exhibit favorable physicochemical properties, including stability, solubility, and a broad theoretical population coverage. Docking and molecular dynamics simulations suggested a potential interaction with Toll-like receptor 4, offering preliminary insight into possible innate immune engagement. As these findings are entirely in silico, they represent a theoretical framework; experimental validation is necessary to determine the construct’s biological behavior, safety, and immunological relevance.